In 2024, Thermal continued to accelerate the understanding and adoption of the world’s most innovative biotechnologies, and achieved numerous PR industry milestones, including: ✅Launching a new breakthrough company each quarter ✅Managing 20+ critical funding and partnership

Nautilus Co-Founder and CEO Sujal Patel was recently featured in @Nasdaq's Amplify Spotlight series. Watch Sujal's interview to learn how we plan to revolutionize biomedicine with the Nautilus Proteome Analysis Platform. https://t.co/H2P1HKqIH1 In the interview, Sujal explains

We’re excited to announcethe promotion of Prashant Nambiar to Chief Scientific Officer and appointment of Ethan Cash to SVP of Program Development! As Strand’s research continues evolve towards clinical trials, these appointments will be vital in securing our success.

Last month at SF @Techweek_, our CEO @ekelsic and Head of Machine Learning @samsinai joined @a16z General Partner @JorgeCondeBio for a conversation about the barriers to treating rare genetic diseases today and a long-term vision of gene therapy as a mainstream treatment option

Jennifer Doudna. Reed Jobs' Yosemite Ventures. Third Rock Ventures. CAR-T. CRISPR. Gladstone. Parker Institute. UCSF. UC Berkeley. Stanford. Startup Azalea Therapeutics' got it all — including a fresh $65 million — to target cancer, autoimmune diseases

We’re proud to announce the successful installation and testing of our first field evaluation unit at the @BuckInstitute! https://t.co/3A4IULHawI The Buck Institute’s deployment of our instrument generates tau proteoform data and provides external validation for our

We’re pleased to announce the final group of speakers at the Genetic Agency Technology Conference (GATC), rounding out our incredible lineup of voices shaping the next generation of genetic technologies. Check out the full lineup of speakers here: https://t.co/kO9xpgSCF0

𝐓𝐞𝐜𝐡 + 𝐓𝐨𝐮𝐫𝐬: BiotechTV visited South San Francisco based @NOETIK_ai and saw how they are digitizing tumor samples and using AI to sort through the complexity of cancer biology for drug discovery. Full video: https://t.co/aET398FQFE

Today on the Nautilus Blog - The second post in our new series focused on AI and proteomics. Dive in to learn how our data’s quality, simple and direct relationship to biology, and scale are designed to make it ideal for AI integration. https://t.co/BsUhDw7DXR #AI

Listen to this episode of the "Few & Far Between" podcast to hear how Nautilus CMO Kentaro Suzuki is shaping the strategy to bring the Nautilus Proteome Analysis Platform to market.

New name & a new model for the 130-employee company fka Genesis Therapeutics Genesis Molecular AI says its newest AI model, PEARL, outperforms AlphaFold 3 and others at predicting protein-ligand structures: https://t.co/pRWmqWZUMG

Excited to share Pearl from Genesis Molecular AI (yes, we've updated our name!): the first co-folding model to clearly surpass AlphaFold 3 on protein-ligand structure prediction. Unlike LLMs that train on vast public data, drug discovery AI faces fundamental data scarcity. Our

Longevity science means different things to different people but @freethinkmedia just published a longevity series that cuts through the noise and is worth your time. Insightful reporting on where the science actually stands — lab breakthroughs, clinical trials, and the

At @Google Zeitgeist 2025, Jennifer Doudna joined @EricTopol and James Manyika to discuss AI, CRISPR, and the future of medicine. https://t.co/owTWdqH6BZ

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease. "I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

Zooming out on AI in biopharma — with Vijay Pande

Proud to see @BenjamineYLiu recognized in @BioSpace’s 40 Under 40 this year! Read the full write-up here:

Congrats to our CEO, @BenjaminLOakes, on being named to @BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.

Congrats to several Thermal clients recognized by BioSpace! 👏 Read about their ongoing achievements, from advancing #CRISPR to #AI for drug discovery and clinical trials, below. @enfeinberg, CEO of Genesis Therapeutics https://t.co/MrEdA4UOmW @BenjamineYLiu, CEO of

I'll be speaking live with @vijaypande about AI in bio. Pande left @a16z this summer after over a decade at the VC firm. He had founded bio/health practice, and we'll talk about his new AI firm: @VZVCfund https://t.co/l76aBSTCW6

Healthcare Investors Vijay Pande, Zack Werner Team Up to Form VZVC -- @BrianPGormley @WSJ https://t.co/gq7386MJCb